High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.

@article{Vitolo2005HighDS,
  title={High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.},
  author={Umberto Vitolo and Anna Marina Liberati and Maria Giuseppina Cabras and Massimo Federico and Emanuele Angelucci and Luca Baldini and Carola Boccomini and Maura Brugiatelli and Roberta Calvi and Giovannino Ciccone and Angelo Genua and Giorgio Lambertenghi Deliliers and Alessandro Levis and Guido Parvis and Enzo Pavone and Flavia Salvi and Marco Sborgia and Eugenio Gallo},
  journal={Haematologica},
  year={2005},
  volume={90 6},
  pages={793-801}
}
BACKGROUND AND OBJECTIVES Poor prognosis diffuse large cell lymphoma (DLCL) responds poorly to standard chemotherapy. Randomized studies comparing high-dose chemotherapy with autologous stem-cell transplantation (ASCT) against standard chemotherapy have produced conflicting results. Dose-dense chemotherapy with granulocyte colony-stimulating factor (G-CSF) support seems to hold promise. The purpose of this multicenter, randomized trial was to compare failure-free and overall survival in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2016
View 4 Excerpts
Highly Influenced

Autologous Stem Cell Transplantation for Aggressive Lymphomas

Mediterranean journal of hematology and infectious diseases • 2012
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Dose intense , every two week chemotherapy ( CHOP - DI ) may improve survival in intermediate and high grade lymphoma . The Southwest Oncology Group

DW Blayney, ML LeBlanc, +3 authors CH Spiridonidis
J Clin Oncol • 2003

Dose intense, every two week chemotherapy (CHOP-DI) may improve survival in intermediate and high grade lym phoma

DW Blayney, ML LeBlanc, +3 authors CH Spiridonidis
The Southwest Oncology Group. J Clin Oncol 2003;21:2466-73 • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…